Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #1491 on VG Life Sciences Inc. (VGLS)
palmspringsbum
02/02/11 11:01 PM
#1492 RE: davidam #1491
Although it has great potential, we are leaving VG Energy out of our IV methodology and treating it as a free out-of-the-money call option. Our base case IV model values Viral’s shares at $0.47. It assumes the company is successful in Phase 1 and 2 clinical trials with its HIV and drug-resistant cancer therapies, and is further able to strike licensing deals with established biopharmaceutical companies to complete clinical testing and take on the market within the next 3-5 years.
With the successful conclusion of the lawsuit, we expect Viral to return to full reporting and list on the OTCBB.